Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus Nephritis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN). Basic parameters: from 19 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Non Invasive Assessment of Subclinical Atherosclerosis in Relation to Triglyceride-Glucose (TyG) Index and Cardiovascular Risk in Lupus Nephritis a Single Center study_Assuit University
Overview
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of immune tolerance, autoantibody production, immune complex deposition, and complement activation, resulting in widespread inflammation and organ damage. Renal involvement, known as lupus nephritis (LN), occurs in approximately 40-60% of SLE patients and represents one of the most severe disease manifestations, significantly contributing to morbidity and mortality.Lupus nephritis arises from immune complex deposition in glomerular and tubulointerstitial structures, causing inflammatory and proliferative lesions that can progress to chronic kidney disease or end-stage renal disease. The ISN/RPS classification provides a standardized histopathological framework essential for prognosis and guiding treatment decisions. In addition to renal complications, patients with SLE and LN are at substantially increased risk of premature cardiovascular disease, which cannot be fully explained by traditional cardiovascular risk factors.Persistent systemic inflammation, endothelial dysfunction, dyslipidemia, and insulin resistance accelerate atherosclerosis in these patients. Subclinical vascular changes, including increased carotid intima-media thickness (CIMT) and carotid plaque formation, often precede overt cardiovascular events, underscoring the importance of early cardiovascular risk assessment The triglyceride-glucose (TyG) index is a validated surrogate marker of insulin resistance, correlating with endothelial dysfunction, subclinical atherosclerosis, and increased CIMT Elevated TyG index may therefore serve as a simple, non-invasive tool for early cardiovascular risk stratification in patients with lupus nephritis
Detailed description
the study is asingle center observational study will be conducted at Assiut University Hospital,Internal medicine departement, ,Rheumatology and Renal unit(inpatient,\_outpatient clinics) including :Full history taking and thorough clinical examination including:
* Demographic Information: Collect data on age, gender, duration of illness, and relevant medical history. * Body Mass Index (BMI) * smoking status and Medications history as (corticosteroids, immunosuppressants and anti lipidemic drugs to be excluded) * Clinical Assessment: patients diagnosed as SLE according to 2019 EULAR/ACR classification criteria. and lupus nephritis (LN) , classified according to the 2018 ISN/RPS classification of lupus nephritis.and Assessment of SLE disease activity according to SLEADI-2K score. * Laboratory Tests: * Combelete blood count (CBC) * Lipid profile ( fasting TGS ,total cholesterol, LDL, HDL, VLDL) * Fasting blood glucose (mg/Dl) * Kidney function test (Serum Creatinine ,blood urea nitrogen) * eGFR * CRP * Erthrocyte sedimentation rate (ESR) * Autoantibody Profiles: ANA, anti-dsDNA * Complement Levels: C3, C4 * Urinary protein excretion (24-hour urinary protein ) * Homocysteine * Serum uric acid * Renal biobsy
\- Indices calculation: * Triglyceride-Glucose (TyG) Index * The CRP\_TYG index \_- Carotid Ultrasonography
Primary outcome measures
- 1.Determining whether TyG index independently predicts subclinical atherosclerosis after adjusting for traditional risk factors in patients of systemic lupus erythematosus (SLE) with or without lupus nephritis(LN). [Time frame: baseline (at enrollment)]
Eligibility criteria
Inclusion criteria
- Adults aged ≥18 years
- Diagnosis of SLE according to the 2019 ACR/EULAR classification criteria for systemic lupus erythematosus.
- Lupus nephritis , classified according to the 2018 ISN/RPS classification of lupus nephritis.
Exclusion criteria
- Established cardiovascular disease (MI, stroke, PAD)
- Diabetes mellitus
- Hypertension
- Patient with CKD
- infections
- other autoimmune diseases
- Pregnancy
- Malignancy
- chronic liver disease
- Dyslipidemia
- Obesity
- Patients on lipid lowering therapy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-control
Study locations
Egypt · 1 center
- Assuit university hospitals — Asyut
Identifiers
NCT: NCT07719322 · TYG index and CVS risks in LN